Motherhood and mental illness. Part 2 - Management and medications

Australian Family Physician

Volumn 38, Issue 9, 2009, Pages 688-692

  Frayne, Jacqueline ^a   Nguyen, Thinh ^a   Allen, Suzanna ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; BREAST FEEDING; FEMALE; HUMAN; MENTAL DISEASE; MOTHER; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PSYCHOLOGICAL ASPECT; RISK FACTOR;

BREAST FEEDING; FEMALE; HUMANS; INFANT, NEWBORN; MENTAL DISORDERS; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 74049087083     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Women Ment Health 2005;8:214-20.
2. Bennett P. Communicating about risks to public health: Pointers to good practice. London: Department of Health, EOR Division, 1997.
3. Dodd S, Opie J, Berk M. Pharmacological treatment of anxiety and depression in pregnancy and lactation. In: Castle DJ, Kulkarni J, Abel KM, editors. Mood and anxiety disorders in women. Cambridge: Cambridge University Press, 2006.
4. Priest SR, Barnett B. Perinatal anxiety and depression: Issues, outcomes and interventions. In: Williams AS, Cowling V editors. Infants of parents with mental illness. Australian Academic Press, 2008; p. 25-44.
5. Treatment Protocol Project. Management of mental disorders. 4th edn. Sydney. World Health Organization Collaborating Centre for Evidence in Mental Health Policy, 2004; p. 109-36.
6. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-7.
7. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607-13.
8. Djulus J, Koren G, Einarson TR, et al. Exposure to mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-4.
9. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol 2008;28:279-88.
10. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164:1206-13.
11. Gentile S. Serotonin reuptake inhibitor-induced perinatal complications. Paediatr Drugs 2007;9:97-106.
12. Ferreira E, Carceller AM, Agogué C, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007;119:52-9.
13. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-52.
14. Kulkarni J, McCawley-Elson K, Marston N, et al. Preliminary findings from the National Register of Antipsychotic Medication. Aust N Z J Psychiarty 2008;42:38-44.
15. National Institute for Health and Clinical Excellence. NICE clinical guideline 45, Antenatal and postnatal mental health: Clinical management and service guidance, issue date February 2007 (reissued April 2007). Available at www.nice.org.uk/CG045 [Accessed 23 February 2008].
16. Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: Prospective comparison study. Br J Psychiatry 2008;192:333-7.
17. Viguera A, Nonacs R, Cohen LS, Tondo L, Murray A, Baldassarini RJ. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-84.
18. Pinelli JM, Symington AJ, Cunningham KA, Paes BA. Case report and review of the perinatal implications of maternal lithium use. Am J Obstet Gynecol 2002;187:245-9.
19. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: Fetal deaths and malformations. Neurology 2006;67:407-12.
20. Harden CL. Antiepileptic drug teratogenesis: What are the risks for congenital malformations and adverse cognitive outcome? Int Rev Neurobiol 2008;83:205-13.
21. Rampono J, Kristensen JH, Ilett KF. Antidepressants and antipsychotics. In: Textbook of human lactation. Hale TW, Hartmann P, editors. Amarillo, Texas: Hale Publishing, 2007; p. 535-55.
22. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation. Part 1: Teratology. Obstet Gynecol 2009;113:166-88.
23. Einarson A, Pistelli A, DeSantis M, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Br J Psychiatry 2008;192:333-7.
24. Guclu S, Gol M, Dogan E, Saygili U. Mirtazapine use in resistant hyperemesis gravidarum: Report of three cases and review of the literature. Arch Gynecol Obstet 2005;272:298-300.
25. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study. J Clin Psychiatry 2005;66:444-9.
26. Newport DJ, Calamaras MD, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Drug Saf 2007;30:247-64.
27. Kohen D. Psychotropic medication and breast-feeding. Advances in psychiatric treatment 2005;11:371-9.